OncoMatch/Clinical Trials/NCT06922539
ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
Is NCT06922539 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Fenretinide and Fenretinide for small cell lung cancer.
Treatment: Fenretinide · Fenretinide — This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Patients must have had prior treatment with radiation therapy or with platinum-based chemotherapy ± immunotherapy with no limit on the number of prior systemic treatment regimens.
Must have received: radiation therapy
Patients must have had prior treatment with radiation therapy or with platinum-based chemotherapy ± immunotherapy with no limit on the number of prior systemic treatment regimens.
Cannot have received: chemotherapy or radiotherapy (nitrosoureas, mitomycin C)
Exception: allowed if completed ≥4 weeks prior (≥6 weeks for nitrosoureas or mitomycin C) and recovered from toxicity
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
Lab requirements
Blood counts
normal organ and marrow function
Kidney function
normal organ and marrow function
Liver function
normal organ and marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify